NASDAQ:XERS
Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc.'s revenue grew 43.7% in fiscal 2025 to $291.8M while operating margin rose to 8.5%, its highest in 6 years. The diluted share count rose 17.7%.Summary generated from Xeris Biopharma Holdings, Inc.'s SEC filings. Latest annual report filed Mar 2, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$291.8M
Revenue growth+43.7%
Revenue, 5-yr CAGR+70.2%
Gross marginn/a
Operating margin8.5%
Net margin0.2%
ROIC19.6%
Return on equityn/a
Debt / equity16.10
Free cash flown/a
FCF marginn/a
Share count change+17.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 50 | 110 | 164 | 203 | 292 |
| Operating income | −115 | −82 | −44 | −34 | 25 |
| Net income | −123 | −95 | −62 | −55 | 1 |
| Free cash flow | −97 | n/a | n/a | n/a | n/a |
Recent filings
- 4Insider transaction report
Oct 2, 2026 - 4Insider transaction report
Oct 2, 2026 - 8-KRegulation FD disclosure
Sep 9, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KOther events
Jul 17, 2026 - 8-KDirector or officer change
Jun 30, 2026 - 8-KOther events
Jun 11, 2026